Are you Dr. Pardanani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 58 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st Street SW
Rochester, MN 55905Phone+1 507-284-2511- Is this information wrong?
Summary
- Dr. Animesh Pardanani, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota and South Dakota. He is affiliated with Mayo Clinic Hospital - Rochester and is an Assistant Professor at Mayo Medical School.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1997 - 2000- Mayo Clinic College of MedicineClass of 1992
Certifications & Licensure
MN State Medical License 2000 - 2025
SD State Medical License Active through 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Start of enrollment: 2009 Nov 01
- Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Start of enrollment: 2011 May 01
- Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, Wi...> ;Haematologica. 2024 Mar 28
- Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat> ;Blood Cancer Journal. 2024 Mar 19
- Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.Ayalew Tefferi, Animesh Pardanani> ;Blood Cancer Journal. 2024 Mar 18
- Join now to see all
Hospital Affiliations
Mayo Clinic Hospital - RochesterRochester, Minnesota
